News

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy
A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on ...
BioSpace14d
UPDATE: Second Patient Dies After Receiving Sarepta’s DMD Gene Therapy Elevidys
Sarepta’s shares crashed 41% in premarket trading Monday morning to $21.01 after the biotech reported a second death from ...
Patient Dies After Receiving Sarepta’s Gene Therapy - MSN
Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...
BioPharma Dive14d
Second Duchenne patient dies after receiving Sarepta gene therapy
Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain ...
GEN3mon
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure after being treated with Elevidys, the only gene therapy that has won ...
MedPage Today3mon
Young Patient Dies After Receiving New Gene Therapy for Duchenne Muscular Dystrophy - Medpage Today
Acute liver failure developed in patient receiving Elevidys. A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy delandistrogene ...
MedPage Today14d
Second Patient Dies After Gene Therapy for Duchenne Muscular Dystrophy
A second Duchenne muscular dystrophy patient died after being treated with the gene therapy delandistrogene moxeparvovec (Elevidys), Sarepta Therapeutics said Sunday. Like the first case reported ...
Investopedia1mon
Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies - Investopedia
Rocket Pharmaceuticals shares plummeted 60% Tuesday after the firm said it halted a study of a gene-therapy drug for Danon disease because a patient had a "Serious Adverse Event (SAE)" and later died.
GEN15d
Second DMD Patient Dies After Treatment with Sarepta Gene Therapy
Outside the United States, rights to Elevidys are held by Roche, which generated $4 million in royalty revenue during Q1, and $16.8 million in 2024 on sales of the gene therapy.
Reuters14d
Sarepta shares crash as second patient dies after receiving its gene therapy
Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who had received its gene therapy, Elevidys ...
STAT3mon
Patient dies after receiving Elevidys, Sarepta’s Duchenne therapy
Sarepta Therapeutics said Tuesday that a 16-year-old boy died after receiving Elevidys, its gene therapy for Duchenne muscular dystrophy, the first known death linked to the treatment.
FiercePharma3mon
Patient dies after receiving Sarepta's DMD gene therapy Elevidys
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech said (PDF) Tuesday. The patient suffered ...